AstraZeneca Could Exit Vaccine Business, Reuters Reports
23 August 2022 - 5:57PM
Dow Jones News
--AstraZeneca PLC is mulling an exit of its vaccine business in
the long term, Chief Executive Pascal Soriot told Reuters in an
interview on Tuesday.
--The CEO of the Anglo-Swedish pharma major cited delays and
regulatory issues in the development of its Covid-19 vaccine--which
still hasn't been approved in the U.S.--as the reason behind the
move, Reuters reports.
--Moving forward, Mr. Soriot said the company is looking to
acquire small and medium-sized business specialized in oncology and
cardiovascular treatments, according to Reuters.
Full story: https://reut.rs/3cdemfJ
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
August 23, 2022 11:42 ET (15:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
